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BACKGROUND: The benefits of regional anesthetic techniques are well established. Use of additives to 
local anesthetics can prolong these benefits. The aim of this study was to find out  the effect of adding 
dexmedetomidine to bupivacaine for supraclavicular block.  
METHODS: In this randomized, double-blind study, 70 ASA I & II patients of either sex undergoing 
elective surgeries on the upper limb were given supraclavicular block under ultrasound guidance. Group 
C (n=35) received 38 mL 0.25% bupivacaine + 2mL normal saline and group D received 38 mL 0.25% 
bupivacaine + 1 µg/kg dexmedetomidine (2mL). Patients were observed for, onset of motor and sensory 
block, duration of motor and sensory block, duration of analgesia, sedation score, hemodynamic changes 
and any adverse events.  
RESULTS: In group D, the onset was faster (P< 0.001), durations of sensory and motor block duration 
of  and analgesia were prolonged as compared to group C (P < 0.0001).There was a significant drop in 
heart rate (HR) from the baseline in group D (P < 0.05) at 30, 60, 90 and 120 min. However, none of the 
patients dropped HR below 50/min. Mean Arterial Pressure (MAP) remained unaffected. The patients in 
group D were more effectively sedated than those in group C (P < 0.05). No adverse event was reported in 
either group.  
CONCLUSION: Dexmedetomidine as adjuvant to bupivacaine in supraclavicular block resulted in faster 
action, prolonged motor and sensory block, prolonged analgesia with hemodynamic stability and 
adequate sedation.  
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INTRODUCTION  
 
Surgeries of the upper limb are usually done under 
brachial plexus block. Various agents have been 
tried as adjuvant to increase the duration of post 
operative analgesia provided by local anesthetics 
(LA).We tried dexmedetomidine, an α2 adrenergic 
agent, as an adjuvant to bupivacaine as it has 
sedative, analgesic, sympatholytic and 
cardiovascular stabilizing effects. The aim of this 
study was to compare the postoperative analgesic 
efficacy and the safety of dexmedetomidine for 





After approval from Hospital Ethical Committee, 
a randomized, double-blind, prospective clinical 
study was initiated. Seventy ASA Grade I and II 
patients of either sex, aged 18–60 years, weighing 
30-65 kg undergoing upper limb surgeries were 
selected. Patients with known hypersensitivity to 
LA, hypertension, diabetes mellitus, bleeding 
disorders, cardiac, liver or renal disease, pregnant 
women, infection at the site of injection and pre-
existing peripheral neuropathy were excluded 
from the study. The patients were divided in two 
groups of 35 patients each on the basis of adjunct 
given to them. The randomization was achieved 
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by random number table using a sealed envelope 
technique. The drug solutions were prepared by an 
anesthesiologist who was not involved in the 
study. The two groups were:  
• Group C: control group; received injection 
bupivacaine (0.25%) 38mL plus 2mL normal 
saline, and   
• Group D: study group; received injection 
bupivacaine (0.25%) 38mL plus dexmedetomidine 
1 µg/kg diluted to 2mL.  
Prior to surgery, all patients were fasted for 
six hours. Baseline heart rate, blood pressure and 
oxygen saturation were recorded. In the unaffected 
arm, after securing 18 G intravenous cannula, 
ringer's lactate was started. Premedication with 
anti-anxiety and sedative drugs was not given. All 
the patients received brachial plexus block through 
the supraclavicular approach by an experienced 
anesthesiologist under ultrasound (US) guidance 
(Sonosite Titan
TM
TM US machine with a 6-13 
MHz linear probe). After the brachial plexus was 
identified, the needle was introduced under US 
guidance. Correct position of the needle was 
confirmed by injecting saline boluses (0.5mL) 
before drug injection. After negative aspiration, 
40mL of drug solution was injected.  
Patients were assessed by a different 
anesthetist for hemodynamic changes, onset of 
motor and sensory blockade, duration of motor 
and sensory block, duration of analgesia, sedation 
score, and any adverse events. Both anesthetists 
were blinded to the treatment groups. Monitoring 
of vital parameters (HR and MAP) was done every 
five minutes for the first 30 minutes and thereafter 
every 10 minutes till the end of surgery and every 
60 minutes(min) post-operatively. Bradycardia 
was defined as HR less than 50 beats/min which 
was treated with inj. atropine 0.6mg i.v.  
Sensory block was assessed by the pin prick 
method at every three minute after drug injection 
by three point scale. According to this scale, (1) 
grade 0 was no block, grade 1 was sensory 
blockade with persistence of touch and grade 2 
was complete sensory blockade. Onset of sensory 
block was the time from drug injection to grade 2 
block. The duration of sensory block was the time 
from drug injection to the complete resolution of 
anesthesia.  
Assessment of motor block was done using 
modified Bromage scale (2) by the same observer 
at every three minute until complete motor 
blockade. According to this scale, grade 0 was free 
movement of elbow, wrist and fingers, grade 1 
was inability to extend the arm for 2 second, grade 
2 was inability to extend the arm or flex the 
forearm, and grade 3 was inability to extend the 
arm, flex the forearm or move the fingers. Motor 
blockade of elbow was checked only in those 
cases in which it was possible; otherwise, only the 
movement of fingers was assessed.  
The onset of motor block was the time from 
drug injection to grade 3 block. The duration of 
motor block was the time from drug injection to 
the complete recovery of motor function of the 
hand and forearm. The block was considered 
incomplete when any of the segments supplied by 
median, radial, ulnar and musculocutaneous nerve 
did not have complete sensory or motor block 
even after 30 minutes of drug injection. These 
patients were then excluded from the study and 
were given general anesthesia. For assessment of 
sedation of patients, Ramsay Sedation Score (3) 
was used.  
Grade 1: Patient anxious and agitated or restless, 
or both  
Grade 2: Patient cooperative, oriented and tranquil  
Grade 3: Patient responds to commands only  
Grade 4: Patient exhibits brisk response to light 
glabellar tap or loud auditory stimulus  
Grade 5: Patient exhibits a sluggish response to 
light glabellar tap or loud auditory stimulus  
Grade 6: Patient exhibits no response.  
The assessment of postoperative pain was 
done hourly in the recovery room and in surgical 
ward with the help of Numeric Rating Scale (1-10) 
(4). Zero was considered as no pain, 1-3 as mild 
pain, 4-6 as moderate pain and 7-10 as severe 
pain. At score of 4, rescue analgesic (inj. 
diclofenac sodium (1.5 mg/kg) intramuscularly) 
was given. Duration of analgesia was the time 
from drug injection to the time of first request of 
analgesia. An attending nurse was advised to 
repeat Inj. diclofenac 1.5 mg/kg every eight hours 
thereafter. All patients were observed for any side-
effects like nausea, vomiting, dryness of mouth, 
pneumothorax, hematoma, local anesthetic 
toxicity and post-block neuropathy in the intra- 
and postoperative periods.  
Keeping the time of first analgesic request as 
primary variable, sample size was calculated. A 
pilot study with five patients in each group 
was conducted. Presuming the difference in 




the time of first analgesic request and effect 
size obtained to be true, we calculated that 35 
patients would be required in each group for 
the study with power 0.8 and significance of 
0.05.The data was coded, entered and analysed 
using SPSS (standard statistical software SPSS) 
software Inc., version 16.0 for windows. Data was 
summarized using mean, standard deviation, 
minimum and maximum for quantitative variables 
and relative frequencies (percentages) for 
categorical variables. Normally distributed 
variables between the two groups were analysed 
using t-tests. Non-normally distributed variables 
were analysed using Mann Whitney test. 
Categorical variables were analysed using the 
Pearson's Chi-square (χ2) test. Fisher exact test 
was used instead when the expected frequency is 
less than 5. P < 0.05 was considered as statistically 




The patients in both groups were comparable with 
respect to the demographic parameters. The 
baseline hemodynamic parameters were 
comparable in both groups. In group D, HR was 
significantly decreased from the baseline at 30, 60, 
90 and 120 minutes as compared to group C 
(Figure 1) (P <0.001) but none of the patients 
developed bradycardia. No statistical difference 
was observed on comparison of mean arterial 
pressures (MAP) between the two groups (Figure 






















































Figure 2: Comparison of Mean arterial pressures between groups 
 





The onset of sensory and motor block was faster 
in group D as compared to group C (P <0.001) 
(Table 1). The duration of sensory and motor 
blockade was significantly prolonged in group D 
(P <0.0001) (Table 1). Similarly, the duration of 
analgesia was also significantly prolonged in 
group D as compared to group C (P <0.0001) 
(Table 1). In group D, none of the patients was 
anxious. RSS 2 was seen in 83% of patients of 
group D while in group C, 85% of the patients had 
sedation score of 1 (Table 3) No adverse effects of 
drugs or complications of the technique were 
observed in any group. 
Table 1: Demographic characteristics 
 
Demographic parameters  Group C (n=35) 
Mean±  S.D 
Group D (n=35) 
Mean±  S.D 
Age (years) 38± 10.9 37.6± 9.3 
Weight (kilograms) 50± 8.9 52± 8.7 
Gender (Male/ Female) 17/18 20/15 
 
Table 2: Onset, duration of sensory & motor block & duration of analgesia 
 
Parameter Group C (n= 35) 
Mean±  S.D 
Group D (n=35) 
Mean±  S.D  
t- value P –value 
Onset of sensory block ( min) 14.76±  3.24 
 
12.24± 2.8 3.48 0.001 
Onset of motor block (min) 20.53± 2.43 15.8± 1.9 9.07 0.0001 
Duration of sensory block (min) 200± 33.85 698± 43.9 53.14 0.0001 
Duration of motor block (min) 188± 28.67 673± 79.46 33.96 0.0001 
Duration of analgesia (min) 210± 35.88 722± 88.45 31.73 0.0001 
 
 
Table 3:  Comparison of Sedation scores 
 
 
Sedation score (RSS) Group C (n= 35) 
 
Group D (n= 35) 
 
1 30(85%) 0 
2 5  (15) 29(83%) 
3 - 6 (17%) 
4 - - 
5 - - 
6 - - 
 




Dexmedetomidine, a highly selective alpha-2 
agonist, has sedative, analgesic, sympatholytic and 
cardiovascular stabilizing effects (5). It causes 
significant opioid sparing as well as a decreased 
requirement of inhalational agents during 
anesthesia. (6) Various studies have shown that 
dexmedetomidine when added to LA in regional 









greater palatine nerve block(14))  causes 
prolongation of duration of block and 
postoperative analgesia.  
The highly selective action of dexmedetomidine 
on alpha-2 adrenoreceptors (α2:α1= 1620:1) 
results in sedation and analgesia without unwanted 
vascular effects from activation of alpha1-
receptors. In addition, a reversal drug 
(Atipamezole) for the sedative effect of 
dexmedetomidine is also available. These 
properties make dexmedetomidine a suitable agent 
for sedation and analgesia during the perioperative 
period. (15) Dose of 1 μg/kg of dexmedetomidine 
was used for supra clavicular block in our study. 




Similar dose were also used in previous studies. 
(11, 12) The use of ultrasound gave us the 
advantage of real time monitoring of drug 
injection around the plexus. However, the volume 
of bupivacaine used was not decreased because 
volume rather than the concentration of LA was 
important to achieve an effective nerve blockade. 
(16) 
Significant drop in HR from the baseline was 
observed in patients of group D. However, none of 
the patients developed bradycardia or hypotension. 
The reduction in HR occurred due to the 
sympatholytic effect of alpha-2 agonists (11). 
Various studies which used dexmedetomidine in 
dose similar to our study, few of them had 
reported cases of bradycardia requiring treatment, 
(11,17,18) while others had not reported any 
incidence of bradycardia (12). 
The onset of sensory and motor blockade was 
faster in the group receiving dexmedetomidine 
than in the control group. The faster onset could 
be due to local action of dexmedetomidine on 
nerve compound action potential (19) as well as 
enhancement of anesthetic action of LA (20). The 
results were in agreement with previous studies in 
which dexmedetomidine was added to 
bupivacaine in supraclavicular block 
(11,12,18,21). 
The duration of motor and sensory block as 
well as post operative analgesia was prolonged in 
group D.  The result can be explained by 
peripheral and central actions of 
dexmedetomidine. Peripherally, it produces 
analgesia by decreasing the release of 
norepinephrine which causes inhibition of on 
nerve action potentials. Centrally, it causes 
inhibition of the release of substance P in the 
nociceptive pathway at the level of the dorsal root 
neuron which produces analgesia (11). 
The patients in group D were comfortable 
and did not require any sedative. This was due to 
the sedative effect of dexmedetomidine by virtue 
of its action on the subtype A and C of alpha-2 
adrenoreceptors in the CNS (locus coerulus) 
which results in sedation, analgesia and anxiolysis. 
(15)
 
In conclusion, dexmedetomidine is an 
effective adjuvant to bupivacaine for 
supraclavicular block. It results in faster onset 
of block with prolonged duration of analgesia, 
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